retatrutide phase 2 study results Weight loss with as compared to licenced obesity Eli Lilly infiltrates anti-obesity market

Safety Considerations and NHS Prescribing Guidelines GLP-1 receptor agonists are generally well-tolerated, but prescribers and patients must be aware of common adverse effects and safety considerations outlined in MHRA guidance and product characteristics

Why GLP-1 Medications Require Nutritional Support The effects of GLP-1 medications on the body don't take long to manifest

Earlier this week, Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial Zepbound (tirzepatide) to patients in the virtual care companies' full-service weight loss management programs

2011 Nov;52(6):892-7 J Biol Chem